We are excited that our VP of clinical development, Melanie Brandabur M.D., will participate in a webinar on September 4th, focused on innovations in gene therapies for Parkinson’s disease, hosted by Cure Parkinson’s. The event is presented in partnership with the Journal of Parkinson’s Disease and chaired by the University of Edinburgh’s Professor Tilo Kunath. The webinar takes place Wednesday, September 4th, 12-1 pm EST. We hope that you can join! You can register here: https://lnkd.in/gWKbYi_E #GeneTherapy #ParkinsonsResearch #Innovation
Capsida Biotherapeutics
Biotechnology
Newbury Park, CA 13,119 followers
Engineering novel AAVs and developing the next generation of gene therapies
About us
Capsida Biotherapeutics Inc. is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening genetic disorders. Capsida's technology allows for the targeted penetration of cells and organs, while limiting collateral impact on non-targeted cells and organs, especially the liver. This technology allows for the delivery of the gene therapy in a non-invasive way through intravenous administration. Capsida's technology is protected by a growing intellectual property portfolio which includes more than 30 patent applications and one issued U.S. patent 11,149,256. The company is exploring using the technology across a broad range of life-threatening genetic disorders. Its initial pipeline consists of multiple neurologic disease programs. The company has strategic collaborations with AbbVie and CRISPR, which provide independent validation of Capsida's technology and capabilities. Capsida is a multi-functional and fully integrated biotechnology company with proprietary adeno-associated virus (AAV) engineering, multi-modality cargo development and optimization, translational biology, process development and state-of-the-art manufacturing, and broad clinical development experience. Capsida's biologically driven, high-throughput AAV engineering and cargo optimization platform originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at the California Institute of Technology.
- Website
-
http://www.capsida.com
External link for Capsida Biotherapeutics
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Newbury Park, CA
- Type
- Privately Held
- Founded
- 2019
- Specialties
- Biotechnology, AAV Engineering, Gene Therapy, Biopharmaceuticals, Protein Engineering, Analytical Development, Process Development, and AAV Immunology
Locations
-
Primary
1290 Rancho Conejo Blvd
Newbury Park, CA 91320, US
Employees at Capsida Biotherapeutics
Updates
-
Thank you, Caroline Jewett for speaking with our Capsida Women's Alliance (CWA) on August 15th! Caroline, Head of Quality at Genelux Corporation, shared valuable insights on her career journey, the distinctions between mentoring and coaching, and strategies for navigating today's dynamic industry. Her perspective was truly inspiring and sparked great discussion within our group. The Capsida Women's Alliance is one of our employee-led resource groups, dedicated to creating and maintaining an inclusive space for all female employees. The group focuses on addressing career and personal issues relevant to women, spotlighting accomplishments in science and business, and establishing a resource for female perspectives and mentoring within the company. What key insights have you gained from mentoring or coaching in your career? Tell us in the comments below! #Leadership #Management #WomenInLeadership #WomenInSTEM #DiversityAndInclusion #WorkplaceEquality #InItTogether
-
-
Capsida Biotherapeutics reposted this
Proud for Capsida Biotherapeutics to be featured as one of the top 10 neuroscience biotechs…
We are pleased to be featured in Labiotech.eu's roundup of top neuroscience biotech companies. This recognition highlights our dedication to advancing gene therapies for neurological disorders. It’s an exciting time for the field, and we’re proud to be a leading innovator driving progress in neuroscience. #neuroscience #genetherapy #biotech #innovation
-
We are pleased to be featured in Labiotech.eu's roundup of top neuroscience biotech companies. This recognition highlights our dedication to advancing gene therapies for neurological disorders. It’s an exciting time for the field, and we’re proud to be a leading innovator driving progress in neuroscience. #neuroscience #genetherapy #biotech #innovation
10 neuroscience biotech companies you should know about
https://www.labiotech.eu
-
This summer, we had the incredible opportunity to host a talented group of interns from Moorpark College. Our interns dove headfirst into the world of gene therapy, gaining hands-on experience in our lab and contributing to our mission of unlocking the potential for gene therapy for all. We are thrilled to see the passion and dedication these students bring to their work. They developed valuable skills and insights while making meaningful contributions to our projects and pushing the boundaries of what's possible in gene therapy. It's been an enriching experience! As we wrap up the summer internship, we’re excited to continue this journey into the fall, nurturing the next generation of innovators and leaders in the field of gene therapy. 📸 Check out some snapshots of our interns in action and a group photo capturing the spirit of collaboration and learning! #GeneTherapy #Internship #Biotech #MoorparkCollege #Capsida #STEMEducation #InItTogether #DrivenByCuriosity #InnovationMeetsExecution
-
Capsida Biotherapeutics reposted this
Celebrating five years with the team! Our annual summer picnic was a day filled with laughter, camaraderie, and a shared sense of pride in how far we've come. Thank you to our amazing team for their hard work, dedication, and for making Capsida the incredible place it is today. Special thanks to the Capsida Culture Committee for putting together such a memorable celebration. Here's to many more years of innovation, progress, and celebrating our shared mission to unlock the potential of gene therapy for all. #CapsidaTeam #CelebratingFiveYears #GeneTherapyInnovation
-
-
Celebrating five years with the team! Our annual summer picnic was a day filled with laughter, camaraderie, and a shared sense of pride in how far we've come. Thank you to our amazing team for their hard work, dedication, and for making Capsida the incredible place it is today. Special thanks to the Capsida Culture Committee for putting together such a memorable celebration. Here's to many more years of innovation, progress, and celebrating our shared mission to unlock the potential of gene therapy for all. #CapsidaTeam #CelebratingFiveYears #GeneTherapyInnovation
-
-
Capsida Biotherapeutics reposted this
Today, I feel an enormous sense of pride as we reflect on Capsida Biotherapeutics five-year journey, focused on the bold mission to unlock the potential of gene therapy for all. Today we celebrate our 5th anniversary with a sense of accomplishment and excitement for the future. As we mark this significant milestone, we look forward to advancing our programs for Parkinson’s disease caused by GBA mutations and genetic epilepsy due to STXBP1 mutations into clinical development in 1H 2025. With a commitment to patients and a culture of innovation, we are dedicated to making the impossible possible and transforming lives through the power of gene therapy. We are grateful to our trailblazing founders Viviana Gradinaru, Nicholas Flytzanis, and Nicholas Goeden for paving the way and to our talented team of Capsidians! Thank you to our dedicated team, partners, investors, patient communities, and healthcare professionals for their unwavering support on this remarkable journey! #CapsidaAnniversary #GeneTherapyInnovation #UnlockingPotential
-
-
Capsida Biotherapeutics reposted this
Today, I feel an enormous sense of pride as we reflect on Capsida Biotherapeutics five-year journey, focused on the bold mission to unlock the potential of gene therapy for all. Today we celebrate our 5th anniversary with a sense of accomplishment and excitement for the future. As we mark this significant milestone, we look forward to advancing our programs for Parkinson’s disease caused by GBA mutations and genetic epilepsy due to STXBP1 mutations into clinical development in 1H 2025. With a commitment to patients and a culture of innovation, we are dedicated to making the impossible possible and transforming lives through the power of gene therapy. We are grateful to our trailblazing founders Viviana Gradinaru, Nicholas Flytzanis, and Nicholas Goeden for paving the way and to our talented team of Capsidians! Thank you to our dedicated team, partners, investors, patient communities, and healthcare professionals for their unwavering support on this remarkable journey! #CapsidaAnniversary #GeneTherapyInnovation #UnlockingPotential
-
-
Back in 2019, we officially became a company with foundational adeno-associated virus (AAV) engineering technology from Viviana Gradinaru’s lab at Caltech. It was both energizing and challenging! We have grown so much over the past 5 years and are so proud of our fully integrated research, development and manufacturing capabilities. Ever since we started, our mission has been to unlock the potential of gene therapy to all. Thank you to everyone who has joined us on our journey! As we celebrate our 5th anniversary, the milestone has prompted us to reflect on our company's core values and culture that helped get us here. In it together We harness the power of our diverse backgrounds and thoughts to deliver on our purpose. We have a sense of collective responsibility and unity. Driven by curiosity We approach every challenge with energy and excitement. We remain resilient in the face of adversity because we understand innovative science is not easy Innovation meets execution We blend innovation with execution in the pursuit to improve patient lives. We’re not limited by the way things have always been done. At our core also lies a commitment to patient advocacy. Beyond our pipeline we champion our patient communities. Executive Director and Head of human resources, Denny Muha, reflects on what it means to be a Capsidian: “To make the impossible, possible and to have the chance to transform and save people’s lives, every day we encourage and challenge each other to live up to our potential as a gene therapy leader. And we are grateful for that.” And if this sounds like you, keep in touch with our careers page for future opportunities: https://lnkd.in/g9NuE5Q3 #CapsidaCulture #DrivenByCuriosity